We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness of Anti-Psychotic in GPs Setting (Serenity)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00543088
First Posted: October 12, 2007
Last Update Posted: April 23, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
October 11, 2007
October 12, 2007
April 23, 2009
January 2007
Not Provided
to evaluate the patient's functioning, by measuring the Quality of Life. Quality of Life will be assessed by the Q-LES-Q-16 (PRO).
Not Provided
Complete list of historical versions of study NCT00543088 on ClinicalTrials.gov Archive Site
  • The clinical efficacy & tolerability of atypical antipsychotics as assessed by the Clinical Global Impression(CGI) & Patient Global Impression of Change(PGIC)scores.
  • The wellbeing of the patients taking atypical antipsychotics as assessed by the Sheehan Disability Scale(SDS)
Not Provided
Not Provided
Not Provided
 
Effectiveness of Anti-Psychotic in GPs Setting
SERENITY: Evaluating the Effectiveness of Atypical Antipsychotics in the Community - a Prospective, Multicentre, Observational Study to Evaluate the Impact on Quality of Life of GP-Bases Management of Antipsychotic Treatment in Belgium.
Evaluating the effectiveness of atypical antipsychotics in the community - a prospective, multicentre, observational study to evaluate the impact on Quality of Life of GP-based management of antipsychotic treatment in Belgium
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Schizophrenia
  • Bipolar Disorder
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
June 2008
Not Provided

Inclusion Criteria:

  • Patients diagnosed with Schizophrenia or Bipolar Disorder (currently in a manic episode)
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
 
NCT00543088
SRP-NB-SER-2006/1
No
Not Provided
Not Provided
Not Provided
AstraZeneca
Not Provided
Principal Investigator: Pitchot W Pr ULg
AstraZeneca
April 2009